Taku Kobayashi

Taku Kobayashi
Kitasato University · Center for Advanced IBD Research and Treatment

MD, PhD

About

353
Publications
43,649
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
9,150
Citations
Introduction
Taku Kobayashi currently works at the Center for Advanced IBD Research and Treatment, Kitasato University. Taku does research in Clinical Immunology and Gastroenterology. Their most recent publication is 'Certolizumab pegol for induction of remission in Crohn's disease'.
Additional affiliations
July 2012 - present
Kitasato University
Position
  • Kitasato University Kitasato Institute Hospital
June 2009 - June 2012
June 2004 - May 2009
Keio University
Education
April 1992 - March 1998
Nagoya University
Field of study
  • Medicine

Publications

Publications (353)
Article
Despite the availability of several biologics for ulcerative colitis (UC), there remains a critical need to identify first-line treatment biologics. The superiority of infliximab (IFX) over vedolizumab (VED) and ustekinumab (UST) was evaluated as initial UC treatments in patients with biologic-naïve UC. This multicenter, randomized control trial wa...
Article
Background Information on infectious complications following acute severe ulcerative colitis (ASUC) is limited. The aim of this study was to determine rates of infections following ASUC treatment and the associated risk factors, using data from the Asian Organization for Crohn’s and Colitis (AOCC) and the Australia New Zealand IBD Consortium (ANZIB...
Article
Background Mirikizumab (miri), an anti-IL-23p19 monoclonal antibody, is effective in inducing clinical remission at week (W)12, maintenance at W52, and providing long-term benefit up to W152 in patients with moderately-to-severely active ulcerative colitis (UC)1. Outcomes in the extended induction population have been reported at W52 and W1042, 3....
Article
Background There are limited comparisons of clinical outcomes of acute severe ulcerative colitis (ASUC) between East Asian (EA) and Western countries and many currently used scoring systems are based on Western populations. We developed a predictive model using ASUC data from EA patients and assessed its ability to predict clinical outcomes in an A...
Article
Background Even after resolving pandemic, the verification of COVID-19 vaccination is important to optimise vaccination against next crisis.1,2 Methods Data at 39 institutes were prospectively acquired at eight predetermined timepoints before and after three manufacturers’ recommended vaccine doses including 3rd booster vaccination in a multicentr...
Article
Background We previously reported that upadacitinib (UPA) demonstrated higher effectiveness than filgotinib (FIL) in the treatment of ulcerative colitis (UC) [1]. We aimed to compare safety profiles between FIL and UPA. Methods A multicenter, retrospective observational study was conducted in patients with UC over 18 years old who received FIL or...
Article
Background Patients with ulcerative colitis (UC) may have bowel urgency (BU), which has been recognised as important due to its links with anxiety, depression, and reduced social quality of life. This study examines intestinal ultrasound (IUS) findings associated with BU, comparing them to endoscopic findings and biomarkers. Methods This prospecti...
Article
Background Acute severe ulcerative colitis (ASUC) is a medical emergency with a potential need for emergency colectomy. Infliximab (IFX) is a safe and effective rescue therapy for patients with steroid-refractory ASUC. Despite being increasingly practiced, there is no evidence that intensified/accelerated IFX regimens are superior to standard induc...
Article
Background Mucosal histological activity is increasingly valued as a treatment endpoint in inflammatory bowel diseases (IBD). In the Asia Pacific region, however, the utility and acceptability of IBD histology as a treatment endpoint is uncertain due to the heterogeneity of IBD prevalence, resourcing, and level of knowledge among practitioners. The...
Article
Full-text available
Background Intestinal ultrasound (IUS) is a non‐invasive tool for evaluating transmural inflammation in Crohn's disease (CD). However, its utility is constrained by operator dependency and limited accessibility. Aims To explore the feasibility of serum biomarkers—specifically leucine‐rich alpha‐2 glycoprotein (LRG)—as an alternative to IUS for ass...
Article
Full-text available
Background The involvement of Mediterranean fever (MEFV) gene mutations in patients with inflammatory bowel disease unclassified (IBDU) remains unclear. This study aimed to determine the clinical characteristics and responsiveness to colchicine in Japanese patients with IBDU carrying MEFV mutations. Methods In this retrospective cohort study, we e...
Article
Full-text available
Background Janus kinase (JAK) inhibitors, filgotinib (FIL) and upadacitinib (UPA) have emerged as promising treatments for ulcerative colitis (UC). However, a comparative analysis of these JAK inhibitors, particularly in patients previously treated with tofacitinib (TOF), has not been performed. Aims To compare the efficacy and safety of FIL and U...
Article
Full-text available
The lack of clear definition and classification for “moderate ulcerative colitis (UC)” creates ambiguity regarding the suitability of step-up versus top-down treatment approaches. In this paper, experts address crucial gaps in assessing and managing moderate UC. The Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition comprise...
Article
Full-text available
To accurately understand the disease activity of Crohn's disease, which causes transmural inflammation of the intestines, cross-sectional imaging is indispensable. The evaluation methods include intestinal ultrasound, computed tomography, and magnetic resonance enterography. It has been reported that the disappearance of transmural inflammation dep...
Article
Background Mirikizumab, a p19-directed interleukin-23 monoclonal antibody, has demonstrated induction of clinical remission at week 12 with maintenance through week 104 in patients with moderately-to-severely active ulcerative colitis (UC). Results are presented from the LUCENT-3 open-label extension study through week 152. Methods Of 868 LUCENT c...
Article
Full-text available
Intestinal ultrasound(IUS)is a valuable tool for noninvasive and rapid decision-making of treatment plans in the management of inflammatory bowel disease(IBD). It is particularly effective in assessing the efficacy of induction therapy, monitoring the maintenance phase, and treating patients with complications such as abscesses and strictures. Incr...
Article
Background/aims: Selecting an optimal advanced therapy for ulcerative colitis (UC) is difficult because of the increasing number of available therapies. This study assessed UC patients' preferences for drug profiles in decision-making regarding advanced therapies using conjoint analysis. Methods: A web-based survey was conducted from October to...
Article
Full-text available
Introduction: There is a close relationship between the relapse of inflammatory bowel disease (IBD) and lifestyle factors, including concomitant medications such as non-steroidal anti-inflammatory drugs (NSAIDs), antithrombotic drugs, smoking status, and alcohol consumption. However, solid evidence is limited regarding the risk factors at diagnosis...
Article
Full-text available
Background Mucosal healing (MH) is an established treatment goal in inflammatory bowel disease (IBD). However, various definitions of MH exist. We aimed to identify how MH is defined in randomized controlled trials (RCTs) in ulcerative colitis (UC) and Crohn's disease (CD). Methods We searched MEDLINE, EMBASE, and the Cochrane library from incepti...
Article
Background/aims: Bowel urgency is an important symptom for quality of life determination in patients with ulcerative colitis (UC). Few clinical studies have focused on bowel urgency as an efficacy endpoint. Budesonide foam enema has shown efficacy for clinical and endoscopic improvement in mild-to-moderate UC. We evaluated the improvement of clini...
Conference Paper
Aim To evaluate long-term efficacy and safety of mirikizumab (miri), a p19-directed IL-23 antibody, in moderately to severely active ulcerative colitis (UC). Methods In LUCENT-3, patients received 200 mg miri Q4W subcutaneously. Results Among W52 miri responders (N=239), 74.5% demonstrated clinical response at W104. Remission rates at W104 for W5...
Conference Paper
Introduction To evaluate clinical response in patients who had not fully responded by the end of the 12-week(W) induction period and who received extended induction treatment for an additional 12W. Methods Patients not responding to intravenous (IV) administration of 300mg mirikizumab (miri) Q4W (n=272) at W12 (LUCENT-1), received extended 12-W in...
Article
This article is the second in a series of two publications on the European Crohn's and Colitis Organisation [ECCO] evidence-based consensus on the management of Crohn's disease. The first article covers medical management; the present article addresses surgical management, including preoperative aspects and drug management before surgery. It also p...
Article
Background/aims: Obtaining and maintaining corticosteroid-free remission are important goals of treatment for ulcerative colitis (UC). Characteristics associated with achieving corticosteroid-free remission were assessed in filgotinib-treated patients in SELECTION, a 58-week, phase 2b/3 trial in moderately to severely active UC. Methods: This po...
Article
Full-text available
BACKGROUND This registry aims to allow for prospective non-interventional observational study of ulcerative colitis. This will facilitate monitoring of the current state of ulcerative colitis in Japan and improving the long-term disease course and adverse events associated with current treatment options. METHODS Inclusion of patients from five cent...
Article
Background/aims: Leucine-rich α-2-glycoprotein (LRG) is a new serum biomarker reflecting the disease activity of ulcerative colitis (UC), but its change during the acute phase has not been enough investigated. Methods: Patients with UC who initiated the induction therapy with steroid or advanced therapy (biologics or Janus kinase inhibitors) wer...
Article
Patients with Crohn’s disease are at higher risk of opportunistic infection, especially if treated with immunosuppressive therapy. Cytomegalovirus has been reported to cause ulcerated lesions mainly in the lower gastrointestinal tract of inflammatory bowel disease patients. We herein report a rare case of Crohn’s disease complicated with cytomegalo...
Article
Background/Aims: Mirikizumab is a p19-directed anti-interleukin-23 antibody with potential efficacy against ulcerative colitis (UC). We evaluated the efficacy and safety of mirikizumab in a Japanese subpopulation with moderately to severely active UC from the LUCENT-1 and LUCENT-2 studies.Methods: LUCENT-1 and LUCENT-2 were phase 3, randomized, dou...
Article
Full-text available
LINKED CONTENT This article is linked to Song et al papers. To view these articles, visit https://doi.org/10.1111/apt.17963 and https://doi.org/10.1111/apt.17999
Article
Full-text available
LINKED CONTENT This article is linked to Lenfant et al papers. To view these articles, visit https://doi.org/10.1111/apt.17753 and https://doi.org/10.1111/apt.17935
Article
Introduction: Treatment goals for ulcerative colitis (UC) are evolving from the achievement of clinical remission to more rigorous goals defined by endoscopic and histologic healing. Achievement of deeper remission targets aims to reduce the risk of colectomy, hospitalizations, and colorectal cancer. Areas covered: This review covers histologic...
Article
Background Mirikizumab, a p19-directed interleukin-23 monoclonal antibody, is efficacious in inducing clinical remission at week 12 (W12) and maintaining clinical remission at W52 in patients with moderately to severely active ulcerative colitis. Results are presented from the open-label extension study through W104. Methods Clinical, symptomatic,...
Article
Full-text available
Background Vedolizumab is an anti-α 4 β 7 integrin antibody used to treat moderate to severe ulcerative colitis (UC) and Crohn’s disease (CD). This post hoc analysis of patient-reported outcomes (PROs) from the VISIBLE 1 (NCT02611830) and 2 (NCT02611817) phase 3 studies evaluated onset of treatment effect on patient-reported symptoms during 6-week...
Article
Hospitalization for ulcerative colitis (UC) is potentially life-threatening. Severe disease in the Japanese criteria which modifies the Truelove–Witts’ criteria might encompass more fulminant cases than the definition for acute severe UC. However, few studies have investigated the predictive factors for clinical remission (CR) after medical treatme...
Article
Full-text available
Background Efficacy and safety of mirikizumab, a p19-targeted anti-interleukin-23 monoclonal antibody, for moderately to severely active ulcerative colitis was demonstrated previously. We evaluated clinical response, baseline characteristics, and clinical status in patients not responding by 12 weeks (W) of induction who then received extended indu...
Article
Background The safety and efficacy of mirikizumab (miri), an anti-IL-23p19 antibody, for moderately-to-severely active ulcerative colitis (UC) have been shown in Phase 3 trials (LUCENT-1 and -2; NCT03518086, NCT03524092).1 Extended induction with 3 additional intravenous (IV) doses of miri induced clinical response at Week (W)24 in more than 50% of...
Article
Background Intravenous steroid therapy (IVS) is the main initial treatment for acute severe ulcerative colitis (ASUC). The study aimed to assess corticosteroid dependency after treating ASUC and to explore potential differences between East Asian and Caucasian populations within the steroid-dependent group. Methods Patients from East Asia (China,...
Article
Background Fistulising perianal diseases (FPD) are common in patients with Crohn's disease (CD) in Asia, but the treatment pattern and the proportion of patients who develop new FPD after diagnosis are not clear. An interim analysis of a large registry study was performed to evaluate the difference in prognosis between patients with and without FPD...
Article
Background Crohn's disease (CD) often leads to the development of intestinal strictures, requiring effective differentiation between inflammatory and fibrotic for the optimal treatment strategies. Despite recent advances in drug development targeting fibrosis, current evaluation methods remain insufficient. Contrast-enhanced ultrasound (CEUS) is a...
Article
Background Infection is one of the concerns in the treatment of inflammatory bowel disease, and advanced age and immunosuppressants are known to be risk factors for infection. However, there has been no studies on infection after acute severe ulcerative colitis (ASUC) and its associated factors. The aim of this study was to investigate infection an...
Article
Background Vedolizumab (VDZ) is a gut-selective monoclonal antibody approved for ulcerative colitis (UC). This real-world study aimed to evaluate the effectiveness of VDZ in the treatment of UC, with the goal of further treatment optimization. Methods In this multicenter, retrospective, observational chart review, 370 patients with UC who received...
Article
Background The 52-week, phase 3 True North (TN) study (NCT02435992) demonstrated the efficacy and safety of ozanimod (OZA), a highly selective sphingosine 1-phosphate receptor 1 and 5 modulator, in patients (pts) with moderately to severely active ulcerative colitis (UC). A prior analysis reported the long-term safety of up to 3 y of OZA in the ong...
Article
Full-text available
LINKED CONTENT This article is linked to Panaccione et al papers. To view these articles, visit https://doi.org/10.1111/apt.17816 and https://doi.org/10.1111/apt.17853
Preprint
Full-text available
During the 20th century, inflammatory bowel disease (IBD) was considered a disease of early-industrialized regions in North America, Europe, and Oceania. At the turn of the 21st century, incidence of IBD increased in newly-industrialized and emerging regions in Africa, Asia, and Latin America, while prevalence in early-industrialized regions starte...
Article
Full-text available
Introduction Whether white blood cell (WBC) counts are predictors for the effectiveness of thiopurine treatment in ulcerative colitis (UC) has been inconclusive in previous studies with small sample sizes. We investigated the association between WBC counts and future relapses in UC patients in a large-scale multi-center study. Methods This retrosp...
Article
Full-text available
Background Single nucleotide polymorphisms (SNPs) of the MEFV gene may modify inflammatory bowel disease (IBD) activity. The prevalence of MEFV gene SNPs in IBD patients and their involvement in IBD pathophysiology remains unclear. Methods We analyzed 12 MEFV gene SNPs in peripheral leukocytes of Japanese IBD patients (Crohn’s disease [CD]: 69 pat...
Article
This multicenter observational cohort study aimed to evaluate the utilization and short-term efficacy of advanced therapy (AT) in hospitalized patients with acute severe ulcerative colitis (ASUC). In total, 221 patients with ASUC were enrolled between August 2020 and July 2021. The primary endpoint was clinical remission (CR, defined as a patient-r...
Article
Background and Aim Strategies to reduce relapse using immunomodulators (IMs) after discontinuing anti‐tumor necrosis factor‐alpha (TNF‐α) antibody treatment are controversial in patients with ulcerative colitis (UC). In this study, we assessed the association between IMs after discontinuing anti‐TNF‐α antibody treatment and relapse in patients with...
Article
Full-text available
As the patents for biologic originator drugs expire, biosimilars are emerging as cost-effective alternatives within healthcare systems. Addressing various challenges in the clinical management of inflammatory bowel disease (IBD) remains crucial. To shed light on physicians’ current knowledge, beliefs, practical approaches, and concerns related to b...
Article
Full-text available
LINKED CONTENT This article is linked to Sagami et al papers. To view these articles, visit https://doi.org/10.1111/apt.16817 and https://doi.org/10.1111/apt.17669
Article
Objectives: Existing endoscopic scores for Ulcerative Colitis (UC) objectively categorize the disease severity based on the presence or absence of endoscopic findings. Therefore, it may not reflect the range of clinical severity within each category. However, Inflammatory bowel disease (IBD) expert endoscopists categorize the severity and diagnose...
Article
Background & aims: The QUASAR Phase 2b Induction Study evaluated the efficacy and safety of guselkumab, an interleukin-23p19 subunit antagonist, in patients with moderately to severely active ulcerative colitis (UC) with prior inadequate response and/or intolerance to corticosteroids, immunosuppressants, or advanced therapy. Methods: In this dou...
Preprint
Full-text available
While biologic originators’ patents are expiring, biosimilars are emerging to take their place, offering significant cost savings to healthcare systems. Many challenges still need to be addressed in the clinical practice of inflammatory bowel disease (IBD). A global survey was organized to highlight physicians’ current knowledge and beliefs and to...
Article
Background: The degree of immune response to COVID-19 vaccination in inflammatory bowel disease (IBD) patients based on actual changes in anti-SARS-CoV-2 antibody titres over time is unknown. Methods: Data were prospectively acquired at four predetermined time points before and after two vaccine doses in a multicentre observational controlled st...
Article
The concept of disease clearance has been proposed as a potential target in ulcerative colitis (UC). We conducted a systematic review to investigate the role of disease clearance, defined as a composite outcome including simultaneous clinical, endoscopic, and histologic remission of disease in the management of patients with UC. Based on the litera...
Article
Full-text available
Although many therapeutic options are available for inflammatory bowel disease (IBD), 5-aminosalicylic acid (5-ASA) is still the key medication, particularly for ulcerative colitis (UC). However, the mechanism of action of 5-ASA remains unclear. The intestinal microbiota plays an important role in the pathophysiology of IBD, and we hypothesized tha...
Article
Full-text available
Introduction Bowel ultrasound is a noninvasive alternative to endoscopy for assessing the disease activity of ulcerative colitis; however, it is unclear whether bowel ultrasound can predict subsequent relapse from remission. Materials and Methods A retrospective cohort study enrolled patients with ulcerative colitis who underwent bowel ultrasound...
Article
Background and aim: Many patients have endoscopic evidence of recurrent Crohn's disease (CD) at one year after intestinal resection. These lesions predict future clinical recurrence. We endoscopically evaluated postoperative anastomotic lesions in CD patients from a large cohort of postoperative CD patients. Methods: We retrospectively enrolled...